Protein C News and Research

RSS
Highly specialized T cells remain in blood 20 months after COVID-19

Highly specialized T cells remain in blood 20 months after COVID-19

Specific area of SARS-CoV-2 spike protein found to be a promising target for pan-coronavirus vaccine

Specific area of SARS-CoV-2 spike protein found to be a promising target for pan-coronavirus vaccine

Study finds specific molecular barriers to SARS-CoV-2 replication in bat cells

Study finds specific molecular barriers to SARS-CoV-2 replication in bat cells

'Western style' diet high in fat and sugar can negatively affect breast milk and baby's health

'Western style' diet high in fat and sugar can negatively affect breast milk and baby's health

Investigating an effective linear deoxyribonucleic acid COVID-19 vaccine option for domestic cats

Investigating an effective linear deoxyribonucleic acid COVID-19 vaccine option for domestic cats

Increased resistance to human interferons could be a potential driver of SARS-CoV-2 evolution

Increased resistance to human interferons could be a potential driver of SARS-CoV-2 evolution

Study shows SARS-CoV-2 impairs interferon production through NSP2-induced repression of mRNA translation

Study shows SARS-CoV-2 impairs interferon production through NSP2-induced repression of mRNA translation

Scientists receive $3.9 million NIH grant to eradicate HIV from the brain

Scientists receive $3.9 million NIH grant to eradicate HIV from the brain

New method could lead to more efficient production of next-generation antibiotics

New method could lead to more efficient production of next-generation antibiotics

Study shows the emerging Omicron sublineage BA.2.75 does not show greater immune evasion than BA.5

Study shows the emerging Omicron sublineage BA.2.75 does not show greater immune evasion than BA.5

Novel compound inhibits SARS-CoV-2 replication by binding a genome target

Novel compound inhibits SARS-CoV-2 replication by binding a genome target

Scientists explore associations between SARS-CoV-2 neutralizing antibodies and receptor-binding domain-selective proliferative memory CD4 T cells

Scientists explore associations between SARS-CoV-2 neutralizing antibodies and receptor-binding domain-selective proliferative memory CD4 T cells

Temporal changes in CD4 T-lymphocyte dynamics upon immunization against SARS-CoV-2 spike protein

Temporal changes in CD4 T-lymphocyte dynamics upon immunization against SARS-CoV-2 spike protein

The neutralizing antibody response in mRNA vaccinated and boosted healthcare workers against major circulating SARS-CoV-2 Omicron subvariants

The neutralizing antibody response in mRNA vaccinated and boosted healthcare workers against major circulating SARS-CoV-2 Omicron subvariants

Study estimates prevalence of SARS-CoV-2 omicron breakthrough infections in South Africa

Study estimates prevalence of SARS-CoV-2 omicron breakthrough infections in South Africa

Nasal spray highly effective against HIV and SARS-CoV-2 in animal models

Nasal spray highly effective against HIV and SARS-CoV-2 in animal models

Three doses of Novavax vaccine effective against Omicron subvariants

Three doses of Novavax vaccine effective against Omicron subvariants

CDC: Novavax's COVID-19 vaccine can be used as another primary series option for adults

CDC: Novavax's COVID-19 vaccine can be used as another primary series option for adults

How has vaccination shaped the global evolutionary trajectory of SARS-CoV-2?

How has vaccination shaped the global evolutionary trajectory of SARS-CoV-2?

SLU and industry partners report the first effective drug to treat rare, genetic liver disease

SLU and industry partners report the first effective drug to treat rare, genetic liver disease

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.